Immuron Limited
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Steven George Lydeamore
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 62 Lygon Street Carlton VIC Australia 3053
- IPO Date
- Jun 9, 2017
- CIK
- 0001660046
- Website
- immuron.com.au
- Similar Companies
- Business
- Immuron Limited, a biopharmaceutical company headquartered in Carlton, Australia, and founded in 1994, develops and commercializes orally delivered polyclonal antibodies derived from hyper-immune bovine colostrum for gastrointestinal health and infectious disease prevention. The company operates through Research and Development and Hyper-immune Products segments, offering Travelan, an over-the-counter medicine and dietary supplement to reduce the risk of travelers' diarrhea, minor gastrointestinal disorders, and support digestive tract protection, available in Australia, Canada, and the United States; Protectyn, an immune supplement supporting healthy gut, liver, and digestive function, sold in Australia; and ProIBS, a clinically proven medicine for relieving irritable bowel syndrome symptoms including abdominal pain, bloating, and bowel irregularities, distributed exclusively in Australia and New Zealand. Immuron conducts business primarily in Australia, the United States, and Canada, targeting consumer health, pharmacy retail, and military health markets with nutraceutical and therapeutic products addressing enteric pathogens like Enterotoxigenic Escherichia coli, Campylobacter, Shigella, and Clostridioides difficile. Recent developments include a March 2025 exclusive distribution agreement with Calmino for ProIBS launch in Australia in first-quarter 2026 following product listing as a complementary medicine; a December 2025 research agreement funded by the U.S. Department of Defense with the Naval Medical Research Command and Walter Reed Army Institute of Research to develop hyper-immune colostrum products targeting Campylobacter jejuni and Shigella sonnei; completion of recruitment for a Travelan (IMM-124E) clinical trial with topline results expected in October 2025 and planned Investigational New Drug submission for IMM-529 against Clostridioides difficile in August 2025; and projected sales exceeding A$7 million for fiscal year 2025, up from A$4.9 million prior year. Formerly known as Anadis Limited until its name change in 2008, Immuron lists on the ASX as IMC and NASDAQ as IMRN.
Company News
Immuron Stock Surges Friday: What's Driving the Action?
Immuron to launch PROIBS® in the United States
Immuron (NASDAQ:IMRN) and Applied Therapeutics (NASDAQ:APLT) Financial Analysis
Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00
Immuron Double Digit 3Q Sales Growth
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target
Immuron Reports Continued Sales Growth
Immuron IMM-529 IND approved by FDA
Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target
Immuron Q1 FY26 YoY growth
Immuron Submits IMM-529 IND to FDA
Immuron Letter to Shareholders – Projects Update
Immuron partners with InvestorHub
Immuron - FY25 global sales exceed projection, up 49% on prior year
Immuron Letter to Shareholders: Projects Update
Immuron Travelan® highest sales in history